Neogap presents innovative tumour-targeting T-cell therapy at Neoantigen Summit Europe
Neogap Therapeutics, a biotech company specialising in personalised immunotherapy, is pleased to announce that Ola Nilsson, Head of Neoantigen Production and Development, will present the company’s innovative cell therapy pTTL at the 6th Annual Neoantigen Summit Europe in Amsterdam on the 24th - 26th of April. The summit is dedicated to advancing personalised therapeutic development through the discovery of exclusive tumour antigens.During the presentation, Ola Nilsson will showcase Neogap's advanced software PIOR[®] for neoantigen prediction and selection and the innovative EpiTCer[®]